The deal includes an upfront payment, and contingent clinical, development and regulatory milestone payments. AMAL Therapeutics is also eligible to receive up to €100m (£89.8m) based on the
The post Boehringer Ingelheim buys Swiss biotech firm AMAL Therapeutics appeared first on Pharmaceutical Business review.
Original Article: Boehringer Ingelheim buys Swiss biotech firm AMAL Therapeutics